Key Points
- Director Sue Gail Eckhardt sold 3,856 shares of Exelixis on Feb. 13 at an average price of $43.79, a transaction that cut her stake by 18.04% and left her with 17,524 shares (SEC filing attached).
- Her sale is part of a wider wave of insider selling this week — including large blocks from an EVP, the CFO and another director — totaling roughly $8–9 million and potentially raising investor governance/insider‑confidence questions.
- Exelixis reported a Q4 EPS beat of $0.94 vs. $0.74 expected with revenue of $598.7M (up 5.6% y/y but slightly below consensus); the stock trades with a market cap around $11.6B and a consensus analyst target near $47.11 (current consensus: Hold).
Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Sue Gail Eckhardt sold 3,856 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.79, for a total value of $168,854.24. Following the transaction, the director owned 17,524 shares of the company's stock, valued at approximately $767,375.96. This trade represents a 18.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Exelixis Stock Up 0.9%
Shares of NASDAQ EXEL opened at $44.47 on Thursday. The stock's 50 day moving average price is $43.77 and its two-hundred day moving average price is $41.13. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The stock has a market capitalization of $11.55 billion, a P/E ratio of 16.05, a PEG ratio of 0.99 and a beta of 0.42.
Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.20. The business had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.55 EPS. On average, analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.
Wall Street Analyst Weigh In
EXEL has been the subject of several research reports. Citigroup lowered shares of Exelixis from a "market outperform" rating to an "underperform" rating in a research report on Monday, January 5th. Wells Fargo & Company boosted their target price on Exelixis from $30.00 to $35.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 11th. Weiss Ratings reissued a "buy (b)" rating on shares of Exelixis in a research report on Thursday, January 22nd. TD Cowen reissued a "buy" rating on shares of Exelixis in a report on Wednesday, November 5th. Finally, Stifel Nicolaus boosted their target price on Exelixis from $43.00 to $44.00 and gave the stock a "hold" rating in a report on Wednesday, February 11th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of "Hold" and an average target price of $47.11.
Get Our Latest Research Report on EXEL
Hedge Funds Weigh In On Exelixis
Several institutional investors and hedge funds have recently made changes to their positions in EXEL. TriaGen Wealth Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter worth approximately $2,024,000. BridgePort Financial Solutions LLC bought a new position in shares of Exelixis during the 3rd quarter valued at about $517,000. Candriam S.C.A. lifted its stake in Exelixis by 18.4% in the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company's stock worth $28,749,000 after purchasing an additional 108,367 shares during the last quarter. Allianz Asset Management GmbH increased its stake in shares of Exelixis by 153.3% in the third quarter. Allianz Asset Management GmbH now owns 2,462,948 shares of the biotechnology company's stock worth $101,720,000 after buying an additional 1,490,520 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in shares of Exelixis in the second quarter worth about $321,000. Institutional investors and hedge funds own 85.27% of the company's stock.
Trending Headlines about Exelixis
Here are the key news stories impacting Exelixis this week:
- Positive Sentiment: Q4 earnings beat — Exelixis reported $0.94 EPS vs. $0.74 expected and y/y revenue growth of 5.6% (revenue $598.7M; slight miss vs. consensus). The EPS beat and margin strength support valuation and cash‑flow expectations. MarketBeat EXEL summary
- Positive Sentiment: Analyst activity is mixed but includes modestly constructive moves — Barclays and Stifel raised price targets to about $44, and the consensus target remains above current levels (~$47.11), giving upside if clinical/commercial momentum continues. Analyst notes
- Positive Sentiment: Institutional buying — several funds (e.g., Goldman Sachs, Mirae Asset ETFs) increased positions, showing continued institutional interest and supporting liquidity. Institutional holdings
- Neutral Sentiment: Technical / valuation context — market cap ~$11.6B, P/E ~16, 50‑day SMA ≈ $43.8 and 200‑day SMA ≈ $41 — stock is between short‑ and long‑term averages, so momentum shifts could move price moderately. Key metrics
- Negative Sentiment: EVP Patrick J. Haley sold 67,814 shares on Feb 17 at ~$43.52 (~$2.95M), trimming his stake by ~15.1%; large executive sales can raise investor concern about insider confidence/timing. SEC filing
- Negative Sentiment: CFO Christopher J. Senner sold 34,278 shares on Feb 13 (~$1.47M) and 30,617 shares on Feb 17 (~$1.34M), reducing his holdings ~3% in each filing — repeated exec sales amplify negative optics. CFO SEC filings
- Negative Sentiment: Director Bob Oliver sold 30,250 shares on Feb 13 at ~$43.81 (~$1.33M), a ~58.9% reduction in his holding, which may trigger governance/insider‑confidence questions. SEC filing
- Negative Sentiment: SVP Brenda Hefti and Director Sue Gail Eckhardt also disclosed sales (Hefti: 18,669 shares at $44.01 on Feb 18; Eckhardt: 3,856 shares at $43.79 on Feb 13), part of aggregate insider sales of roughly $8–9M this week. Hefti SEC filing Eckhardt SEC filing
About Exelixis
(
Get Free Report)
Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.
The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
